CN105008523B - iNOS抑制剂用于增加培养物中病毒产率的用途 - Google Patents

iNOS抑制剂用于增加培养物中病毒产率的用途 Download PDF

Info

Publication number
CN105008523B
CN105008523B CN201480012376.2A CN201480012376A CN105008523B CN 105008523 B CN105008523 B CN 105008523B CN 201480012376 A CN201480012376 A CN 201480012376A CN 105008523 B CN105008523 B CN 105008523B
Authority
CN
China
Prior art keywords
hsv
ata
virus
cells
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480012376.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105008523A (zh
Inventor
P·佩汉
J·阿丁格
A·斯卡里亚
S·沃兹沃思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN105008523A publication Critical patent/CN105008523A/zh
Application granted granted Critical
Publication of CN105008523B publication Critical patent/CN105008523B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480012376.2A 2013-01-08 2014-01-07 iNOS抑制剂用于增加培养物中病毒产率的用途 Active CN105008523B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750175P 2013-01-08 2013-01-08
US61/750,175 2013-01-08
PCT/US2014/010553 WO2014110053A1 (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture

Publications (2)

Publication Number Publication Date
CN105008523A CN105008523A (zh) 2015-10-28
CN105008523B true CN105008523B (zh) 2020-03-27

Family

ID=51167323

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480012376.2A Active CN105008523B (zh) 2013-01-08 2014-01-07 iNOS抑制剂用于增加培养物中病毒产率的用途

Country Status (20)

Country Link
US (2) US11299715B2 (https=)
EP (3) EP2943567B1 (https=)
JP (2) JP6534933B2 (https=)
KR (1) KR102307279B1 (https=)
CN (1) CN105008523B (https=)
AR (1) AR094389A1 (https=)
AU (1) AU2014205604B2 (https=)
BR (2) BR112015016328B1 (https=)
CA (1) CA2897444A1 (https=)
DK (1) DK2943567T3 (https=)
ES (1) ES2651763T3 (https=)
HK (1) HK1249544A1 (https=)
HU (1) HUE037482T2 (https=)
IL (1) IL239824B (https=)
MX (2) MX360470B (https=)
NO (1) NO3050055T3 (https=)
RU (1) RU2676733C2 (https=)
SG (3) SG10201806715TA (https=)
TW (1) TWI608102B (https=)
WO (1) WO2014110053A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
PL3436593T3 (pl) 2016-03-28 2023-03-27 Ultragenyx Pharmaceutical Inc. Sposoby inaktywacji termicznej adenowirusów
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
ES3012649T3 (en) 2016-10-14 2025-04-09 Ultragenyx Pharmaceutical Inc Use of tonicifying agents to enhance recombinant adeno-associated virus yield
JP7142643B2 (ja) 2017-03-22 2022-09-27 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Hdac阻害剤またはrepタンパク質を伴う細胞培養方法
JP7218303B2 (ja) 2017-05-09 2023-02-06 ウルトラジェニックス ファーマシューティカル インコーポレイテッド トランスフェクション試薬を生成するための拡大可能な方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
CN110835622B (zh) * 2018-08-16 2021-04-27 上海药明生物技术有限公司 用于调节哺乳动物细胞乳酸代谢的培养基及其应用
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
BR112022018658A2 (pt) 2020-03-16 2022-12-20 Ultragenyx Pharmaceutical Inc Métodos para potencializar o rendimento de vírus adenoassociado recombinante
WO2023157976A1 (ja) * 2022-02-21 2023-08-24 学校法人日本医科大学 ウイルスベクター生産性増強剤及びウイルスベクターの製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783972B1 (en) * 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
CN1772884A (zh) * 2005-10-18 2006-05-17 中国人民解放军军事医学科学院生物工程研究所 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基
CN101784532A (zh) * 2007-06-29 2010-07-21 韩国化学研究院 新的hiv逆转录酶抑制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
RU2012335C1 (ru) * 1991-07-04 1994-05-15 Уфимский научно-исследовательский институт глазных болезней Ингибитор вируса простого герпеса
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
JP4044131B2 (ja) * 1992-07-31 2008-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ ヘルペスウイルスワクチン
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
US6833271B2 (en) 1996-12-04 2004-12-21 Medi-Cult A/S Serum-free cell culture media
GB9816856D0 (en) * 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US7091029B2 (en) * 2002-09-23 2006-08-15 Applied Genetics Technologies Corporation High titer recombinant AAV production
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783972B1 (en) * 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
CN1772884A (zh) * 2005-10-18 2006-05-17 中国人民解放军军事医学科学院生物工程研究所 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基
CN101784532A (zh) * 2007-06-29 2010-07-21 韩国化学研究院 新的hiv逆转录酶抑制剂

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Anionic compounds as inhibitors of African swine fever virus replication in Vero cells;D.Garcia-Villalon等;《Antiviral Chemistry & Chemotherapy》;19920201;第3卷(第1期);第10页图1 *
Aurintricarboxylic Acid Inhibits the Early Stage of Vaccinia Virus Replication by Targeting both Cellular and Viral Factors;Chad Myskiw等;《JOURNAL OF VIROLOGY》;20070331;第81卷(第6期);第3028页 FIG.1 D及其附图解释 *
Chad Myskiw等.Aurintricarboxylic Acid Inhibits the Early Stage of Vaccinia Virus Replication by Targeting both Cellular and Viral Factors.《JOURNAL OF VIROLOGY》.2007,第81卷(第6期),第3028页 FIG.1 D及其附图解释. *
Herpes simplex virus type 1 infection and glucocorticoid treatment regulate viral yield, glucocorticoid receptor and NF-кB levels;A C Erlandsson等;《Journal of Endocrinology》;20021031;第175卷(第1期);第168页左栏倒数1-2段,图1 *
Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses;Akihiro Otsuki等;《Molecular Therapy》;20080930;第16卷(第9期);第1548页图1b左 *
Inhibition of cytokine-induced JAK=STAT signaling pathways by an endonuclease inhibitor aurintricarboxylic acid;Ching-Wen Chen等;《British Journal of Pharmacology》;20021231;第137卷(第7期);第1017页左栏第2段 *
Macrophage Control of Herpes Simplex Virus Type 1 Replication in the Peripheral Nervous System;Padma Kodukula等;《The Journal of Immunology》;19990301;第162卷(第5期);第2895页摘要 *
Poly(hhydroxy)carboxylates as selective inhibitors of cytomegalovirus and herpes simplex virus replication;J.Neyts等;《Antiviral Chemistry & Chemotherapy》;19920801;第3卷(第4期);第215-222页 *

Also Published As

Publication number Publication date
EP2943567A1 (en) 2015-11-18
IL239824A0 (en) 2015-08-31
ES2651763T3 (es) 2018-01-29
RU2015133205A (ru) 2017-02-14
US20150353899A1 (en) 2015-12-10
CA2897444A1 (en) 2014-07-17
MX378877B (es) 2025-03-10
SG10201806715TA (en) 2018-09-27
HK1214840A1 (en) 2016-08-05
KR102307279B1 (ko) 2021-09-29
EP3266866B1 (en) 2019-03-06
AU2014205604A1 (en) 2015-08-13
HUE037482T2 (hu) 2018-08-28
EP3521420A1 (en) 2019-08-07
BR112015016328B1 (pt) 2023-04-18
NO3050055T3 (https=) 2018-02-10
TWI608102B (zh) 2017-12-11
EP2943567B1 (en) 2017-09-13
JP6837094B2 (ja) 2021-03-03
RU2018144779A3 (https=) 2022-03-02
US11299715B2 (en) 2022-04-12
AU2014205604B2 (en) 2020-01-02
MX360470B (es) 2018-11-05
SG11201505333PA (en) 2015-08-28
DK2943567T3 (en) 2018-01-02
KR20150103275A (ko) 2015-09-09
BR112015016328A2 (https=) 2017-09-05
US20220340883A1 (en) 2022-10-27
JP2019187420A (ja) 2019-10-31
MX2015008861A (es) 2016-04-13
HK1249544A1 (en) 2018-11-02
RU2676733C2 (ru) 2019-01-10
SG10201913130PA (en) 2020-03-30
AR094389A1 (es) 2015-07-29
CN105008523A (zh) 2015-10-28
RU2018144779A (ru) 2019-01-29
WO2014110053A1 (en) 2014-07-17
IL239824B (en) 2019-03-31
EP3266866A1 (en) 2018-01-10
JP2016504913A (ja) 2016-02-18
TW201446965A (zh) 2014-12-16
JP6534933B2 (ja) 2019-06-26
BR122020002822B1 (pt) 2023-04-18

Similar Documents

Publication Publication Date Title
CN105008523B (zh) iNOS抑制剂用于增加培养物中病毒产率的用途
US12275949B2 (en) High-transducing HSV vectors
US20220307052A1 (en) Recombinant herpesvirales vector
RU2795456C2 (ru) ИСПОЛЬЗОВАНИЕ ИНГИБИТОРОВ iNOS ДЛЯ ПОВЫШЕНИЯ УРОЖАЯ ВИРУСОВ В КУЛЬТУРЕ
HK1214840B (en) Use of inos inhibitors to increase viral yield in culture
KR20250124844A (ko) 변형된 단순 포진 바이러스 1형

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant